https://allsci.com/news/research/ai-designed-cancer-minibinders-university-of-bonn/ AllScien 2026-08-21T16:11:22.194264Z Protein charge emerges as key constraint for AI-designed cancer minibinders https://allsci.com/news/research/metabolic-vulnerability-cancer-danish-institute/ AllScien 2026-08-21T16:00:43.972614Z AKR1A1 loss exposes metabolic vulnerability in drug-resistant liver, kidney cancers https://allsci.com/news/licensing-and-partnerships/biosimilar-licensing-deal-alvotech-licenses-two/ AllScien 2026-08-21T15:55:04.953694Z Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m https://allsci.com/news/licensing-and-partnerships/aav-capsid-engineering-vectorbuilder-and-lir-pair/ AllScien 2026-08-21T15:50:58.473456Z VectorBuilder, Lir apply AI to optimize AAV capsids for manufacturing https://allsci.com/news/licensing-and-partnerships/mrna-cancer-vaccines-metis-techbio-and-westvac/ AllScien 2026-08-21T15:46:19.575652Z METiS, WestVac team up on AI-designed personalized mRNA cancer vaccines https://allsci.com/news/funding/ambros-werewolf-merger-merges-with-raises-usd/ AllScien 2026-08-21T15:40:19.303397Z Ambros lands USD 150m financing in Werewolf reverse merger to fund neridronate Phase III https://allsci.com/news/clinical-trials/fda-digital-health-clinical-trials-establishes/ AllScien 2026-08-21T15:22:10.873219Z FDA sets cross-center framework for digital measures in clinical trials https://allsci.com/news/funding/seralutinib-fda-approval-pah-gossamer-bio-secures/ AllScien 2026-08-21T15:14:00.037981Z Gossamer secures up to USD 250m to fund seralutinib through uncertain FDA path https://allsci.com/news/licensing-and-partnerships/ai-antibody-discovery-bristol-myers-squibb-taps/ AllScien 2026-08-21T15:04:36.542492Z Bristol Myers Squibb taps Chai Discovery's generative AI for antibody design across portfolio https://allsci.com/news/first-in-human-trials/egfrviii-t-cell-engager-glioblastoma-adaptin-bio/ AllScien 2026-08-21T15:03:12.409189Z Adaptin Bio opens first-in-human trial of brain-targeted EGFRvIII T cell engager https://allsci.com/news/regulatory/egfrher3-bispecific-adc-cstone-wins-nmpa/ AllScien 2026-08-21T13:48:07.442837Z CStone to put EGFR/HER3 bispecific ADC to first-in-human test in China https://allsci.com/news/clinical-trials/ak157d1-clinical-trials-akeso-advances-third-adc/ AllScien 2026-08-21T13:46:45.881154Z Akeso advances third ADC into clinical trials with B7-H3-targeting AK157D1 https://allsci.com/news/clinical-trials/mrna-vaccine-cervical-cancer-luye-pharma-advances/ AllScien 2026-08-21T10:27:12.840890Z Luye Pharma advances therapeutic mRNA vaccine into Phase II for HPV lesions https://allsci.com/news/clinical-trials/ipsen-kartos-acquisition-navtemadlin-pays-usd/ AllScien 2026-08-21T09:19:12.084846Z Ipsen closes USD 450m deal for Kartos and myelofibrosis asset navtemadlin https://allsci.com/news/ipo-public-listing/hansa-biopharma-us-listing-pursues-ahead-of-fda/ AllScien 2026-08-21T09:13:20.186010Z Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy